Next Century Growth Investors LLC Has $20.08 Million Position in ADMA Biologics Inc $ADMA

Next Century Growth Investors LLC raised its position in ADMA Biologics Inc (NASDAQ:ADMA) by 178.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,100,773 shares of the biotechnology company’s stock after acquiring an additional 705,217 shares during the quarter. ADMA Biologics makes up about 1.4% of Next Century Growth Investors LLC’s investment portfolio, making the stock its 24th largest holding. Next Century Growth Investors LLC’s holdings in ADMA Biologics were worth $20,078,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ADMA. Westfield Capital Management Co. LP acquired a new stake in ADMA Biologics in the third quarter valued at $74,866,000. Capital Research Global Investors lifted its stake in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the last quarter. Caligan Partners LP acquired a new stake in ADMA Biologics in the third quarter valued at $38,653,000. UBS Group AG lifted its stake in ADMA Biologics by 129.9% in the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after acquiring an additional 2,581,670 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in ADMA Biologics by 2,188.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company’s stock valued at $20,814,000 after acquiring an additional 1,091,241 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Raymond James upgraded ADMA Biologics to moderate buy and set a $21 price target, signaling meaningful upside versus recent trading levels.
• Neutral Sentiment: Several law firms reiterated that investors in ADMA Biologics can seek lead-plaintiff status in the already filed class action, with the deadline set for August 10, 2026. Article Title
• Neutral Sentiment: The company continues to face a broad set of investor-rights notices and duplicate lawsuit solicitations from firms including Rosen, Kirby McInerney, Faruqi & Faruqi, and others, keeping the stock in litigation-focused headlines. Article Title
• Negative Sentiment: Multiple class actions allege ADMA Biologics misrepresented its operations and revenue quality, including channel-stuffing claims and internal-control issues, which raises legal and reputational risk for shareholders.

Insider Buying and Selling

In other news, Director Jerrold B. Grossman bought 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.90% of the stock is currently owned by corporate insiders.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $8.21 on Friday. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $21.53. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of 12.07 and a beta of 0.72. The firm’s 50-day simple moving average is $9.17 and its 200 day simple moving average is $14.15. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. During the same period last year, the firm earned $0.11 EPS. The business’s quarterly revenue was down .3% compared to the same quarter last year. As a group, sell-side analysts predict that ADMA Biologics Inc will post 0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ADMA shares. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group cut their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Mizuho dropped their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday. They issued an “outperform” rating and a $21.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.67.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.